The prevalence of drug-drug interactions and reported therapy related side-effects in oncology out-patients
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/10914/Umar-Rashida%20Muhammad-2023.pdf.jpg?sequence=4&isAllowed=y)
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution-NonCommercial 4.0 Internationalhttps://creativecommons.org/licenses/by-nc/4.0/Tarih
2023Yazar
Umar, Rashida MuhammadCan, Zeynep Yeşim
Güven Eke, Ece
Karataş Koçberber, Emine
Ölmez, Ömer Fatih
Üst veri
Tüm öğe kaydını gösterKünye
Umar, R. M., Can, Z. Y., Güven Eke, E., Karataş Koçberber, E. ve Ölmez, Ö. F. (2023). The prevalence of drug-drug interactions and reported therapy related side-effects in oncology out-patients. Clinical and Experimental Health Sciences, 13(1), 212-217. https://doi.org/10.33808/clinexphealthsci.1099582Özet
Objective: The use of multiple medications in cancer patients is unavoidable; thus, adverse drug-drug interactions are frequent. This study aims to assess the prevalence of potential drug interactions in oncology patients visiting the outpatient chemotherapy unit. Method: Demographic and health-related information of patients visiting an outpatient chemotherapy unit was recorded using a pre-prepared form. A comprehensive list of all concurrently used medications was compiled and checked for interactions with the Micromedex online drug interaction tool.Results: A total of 179 adult patients were included. We recorded an average of 9.3 drugs per patient with 79 patients using more than 10 drugs. A total of 1671 drugs including 303 chemotherapeutic agents were assessed for drug-drug interactions. A total of 374 interactions, of which 203 were significant, were recorded in 118 (65.9%) patients with an average of 3.2 interactions per patient. Only 46 major interactions were recorded for anticancer agents. Cyclophosphamide (n=13) and cisplatin (n=12) were involved in most interactions. The number of interactions correlated with the number of drugs used (p=.001) and the presence of comorbidities (p=.002). The presence of comorbidities increased the risk of interaction by 1.21 (p=.04). Recorded side effects were not correlated to drug interactions. Conclusion: Medication review in cancer patients is essential in establishing all medications used by patients. Routine assessment in terms of potential drug interactions and evaluation of these interactions by a qualified pharmacist may help in optimizing patient outcomes.
Kaynak
Clinical and Experimental Health SciencesCilt
13Sayı
1Bağlantı
https://doi.org/10.33808/clinexphealthsci.1099582https://hdl.handle.net/20.500.12511/10914
Koleksiyonlar
- Makale Koleksiyonu [284]
- Makale Koleksiyonu [3790]
- TR-Dizin İndeksli Yayınlar Koleksiyonu [2179]
- WoS İndeksli Yayınlar Koleksiyonu [6677]